Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
Yonhap News English on MSN14h
Samsung Bioepis launches autoimmune disease treatment in U.S.Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Australia's corporate regulator said on Tuesday the country's stock market operator would be required to publish a comparison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback